You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY20 is not expected to be complete until September, 2021.

  1. Corrosion Protection of High-Value Test&Evaluation Assets

    SBC: eSpin Technologies, Inc.            Topic: MDA13T010

    This STTR Phase I proposal proposes to design and develop reactive filter media using nanofiber technology to capture corrosion inducing particulate matter present in coastal region air. The fibrous filter media will be functionalized using ion exchange chemistry which is known to react with salt ions. The media will be characterized for its filtration performance, resistance to airflow, and dus ...

    STTR Phase I 2014 Department of DefenseMissile Defense Agency
  2. Develop and/or Improve Optical Coating Processes for Military Mirrors

    SBC: FLEXIAL CORP.            Topic: N/A

    Develop a titanium, welded metal bellows extendable sunshade to deploy over seeker system optics in kinetic kill vehicles and other military missile systems that employ optical tracking. One object of the sunshade is to offer an alternative technology tohelp improve the durability of optical coatings by minimizing thermal gradients on the coatings as would be generated by free airflow across the ...

    STTR Phase I 2003 Department of DefenseMissile Defense Agency
  3. Developing VSV cytolytics against High-Grade CNS gliomas

    SBC: Oncternal Therapeutics, Inc.            Topic: N/A

    DESCRIPTION (provided by applicant): Despite continued improvements in diagnosis, surgical techniques, and radiation protocols, the available treatments for high-grade malignant glioma are grossly inadequate. The median survival time for most patients with high-grade gliomas is on the order of months. Metastatic tumors with a tropism for the CNS such as lung and breast pose an even greater problem ...

    STTR Phase I 2003 Department of Health and Human ServicesNational Institutes of Health
  4. Development of Compounds for the Prevention and Treatment of Rhabdomyolysis

    SBC: Virtual Drug Development Inc.            Topic: NIDDK

    ? DESCRIPTION (provided by applicant): The goal of this Phase I STTR project is to establish the feasibility of developing a small-molecule therapeutic agent designed to prevent rhabdomyolysis-induced renal failure. Rhabdomyolysis accounts for 7% to 10% of cases of renal failure in the US. Rhabdomyolysis results from muscle injury that leads to the release of myoglobin, which is then deposited ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  5. Gene Expression and Diagnosis of Autoimmune Disease

    SBC: ARTHROCHIP, LLC            Topic: N/A

    DESCRIPTION (provided by the applicant): Autoimmune diseases, such as systemic lupus erythematosus, rheumatoid arthritis, type I diabetes, and multiple sclerosis, are thought to arise from abnormalities of innate or adaptive immune responses. Autoimmune diseases are often difficult to diagnose, as the symptoms can be typical of other conditions and quite vague, such as musculoskeletal complaints ...

    STTR Phase I 2003 Department of Health and Human ServicesNational Institutes of Health
  6. Gene Expression and Diagnosis of Diabetes

    SBC: ARTHROCHIP, LLC            Topic: N/A

    DESCRIPTION (provided by applicant): Autoimmune diseases are difficult to diagnose, as the symptoms can be typical of other conditions and quite vague. No currently available blood test accurately excludes or includes the possibility of an autoimmune disease in a subject, and a battery of tests and a period of observation are usually required. A single test that could readily distinguish between ...

    STTR Phase I 2003 Department of Health and Human ServicesNational Institutes of Health
  7. Targeted Oncolytic VSV as a Prostate Cancer Therapy

    SBC: Oncternal Therapeutics, Inc.            Topic: N/A

    DESCRIPTION (provided by applicant): Prostate cancer is the most common malignancy in men in the United States and the second leading cause of cancer mortality. Unfortunately there is no cure by standard medical treatment. Therefore, novel treatments for this devastating, common disease are desperately needed. Recent progress in the development of targeted oncolytic viral vectors offer a new strat ...

    STTR Phase I 2003 Department of Health and Human ServicesNational Institutes of Health
  8. Targeting DNA damage response pathways for the treatment of advanced lung cancer

    SBC: CUMBERLAND PHARMACEUTICALS INC.            Topic: NIEHS

    DESCRIPTION (provided by applicant): There is an urgent, unmet need for novel therapeutic approaches that are efficacious against lung cancer. Ranking first among cancer deaths in the U.S., this disease has 5-year relative survival rates of lt20%. Most lung cancers are non-small cell (NSCLC, 85% of cases). Curative surgery is not an option for the 80% of NSCLC patients who present with advanced s ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government